The United Kingdom’s vote to leave the European Union triggered market shockwaves across global financial markets on Friday, with the aftershocks of the much-scrutinized referendum hitting markets on the following trading session again. With mounting uncertainty in the air in connection with the so-called Brexit and its possible consequences, numerous corporate insiders stepped up and bought more shares of their companies following the U.K.’s historic decision to leave the EU.
The insider trading anomaly, which is not necessarily an anomaly given the seemingly straightforward explanations as to why insiders tend to beat broader market benchmarks, has been an extremely profitable investment strategy over the past several decades. Information is the greatest commodity in the world and insiders do have a great deal of information about their companies; they hold much more up-to-date and useful information than do journalists, analysts, or investors. But it is not just the information advantage that makes insiders exceptional at trading securities. Their contrarian approach to investing, which involves buying low and selling high, has been the key behind insiders’ investing success. With that in mind, the following article will discuss the insider buying activity recently registered at three companies.
Through extensive research, we have determined that the due diligence that the investors in our database employ, as well as their long-term focus makes them perfect targets to emulate. However, the results of our analysis have also shown that the small-cap picks of these funds can generate much better returns, with the 15 most popular small-cap stocks beating the market by an average of 95 basis points per month (read more details here).
Heavily Indebted Drug Maker Has Board Member Buy Shares
With Valeant Pharmaceuticals Intl Inc. (NYSE:VRX) shares dipping below the $20-price level and trading near their 52-week low of $18.55, the insider buying at the embattled drug maker has been intensifying lately. Lead independent director Thomas W. Ross Sr. bought 4,000 shares on June 13 at prices ranging from $24.37 to $24.41 per share, lifting his holding to 21,882 shares. Mr. Ross was appointed to the company’s Board in early March, so investors may want some other longer-serving employees and Board members buying shares to rebuild confidence in the future of Valeant.
The heavily indebted Canadian drug maker has lost 81% of its market value since the beginning of 2016, and Britons’ decision to leave the European Union is putting even more pressure on the stock. Currency headwinds represents one of the most significant risks for Valeant Pharmaceuticals Intl Inc. (NYSE:VRX), as nearly one-third of the company’s sales were generated outside the United States last year. The company also seeks to reduce its $31 billion-debt load by implementing an asset sale program, with some worrying that the so-called Brexit would harm the process of freeing up much-needed cash. Some analysts, including David Amsellem of Piper Jaffray, believe there is a possibility that the drug maker defaults on its massive debt, so Valeant executives and directors may need to step up to restore some investor confidence (unless they don’t want to risk their own money because such possibility exists).
The number of hedge funds followed by Insider Monkey invested in the Canadian drug maker decreased to 71 from 83 during the first three months of 2016. Those 71 asset managers amassed roughly 35% of the company’s outstanding common stock. Bill Ackman’s Pershing Square Capital Management was the owner of 21.59 million shares of Valeant Pharmaceuticals Intl Inc. (NYSE:VRX) on March 31.
Let’s head to the next page of this insider trading article, where we will discuss the insider buying registered at two other companies.